Strides Pharma receives USFDA approval to manufacture the generic version of Carafate®
Strides Pharma receives USFDA approval for generic Sucralfate Oral Suspension, expanding its portfolio for gastrointestinal disorders.
On May 22, 2024, Strides Pharma Science Limited, based in Bangalore, India, shared that its step-down wholly owned subsidiary, Strides Pharma Global Pte, as per the reports. Limited, Singapore, received approval from the USFDA to manufacture the generic Sucralfate Oral Suspension, 1gm/10ml.
The bioequivalent product shows a similar therapeutic effect to the Reference Listed Drug, Carafate® 1gm/10mL of AbbVie. Sucralfate is prescribed to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.
The market size of the medicine is ~USD 124 Million as per IQVIA (March 2024). The company will launch ~60 new US products within the next three years.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Ab Science überarbeitet Studienzeitpläne nach drei GCP-Inspektionen
Novo Nordisk unterzeichnet einen $2,6B-Deal mit Hengrui für orales GLP-1
Discussion